OABI OmniAb (OABI) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Services-commercial physical & biological research · CIK 0001846253
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
80
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · no price filed
OmniAb insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for OmniAb, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 18 earlier Form 4 trades (code P or S) here by this insider (10 buys, 8 sales), the last on Feb 18, 2026.
- +12.6% median (+12.1% mean) 90-day return after 10 previous buys.
- The trade is 0.4% of the 4,420,492 shares held after it.
- 2 other insiders sold within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO FOEHR MATTHEW W sold about $28.7K of OABI on Apr 7, 2026; 2 other insiders sold within 30 days and 80 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (1 buy, 10 sales), the last on Feb 18, 2026.
- The trade is 2.6% of the 261,483 shares held after it.
- 2 other insiders sold within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive VP, Finance and CFO GUSTAFSON KURT A sold about $10.3K of OABI on Apr 7, 2026; 2 other insiders sold within 30 days and 80 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Feb 18, 2026.
- The trade is 1.8% of the 399,085 shares held after it.
- 2 other insiders sold within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Berkman Charles S sold about $10.7K of OABI on Apr 7, 2026; 2 other insiders sold within 30 days and 80 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Feb 17, 2026.
- The trade is 2.5% of the 392,700 shares held after it.
- 2 other insiders sold within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Berkman Charles S sold about $16.5K of OABI on Feb 18, 2026; 2 other insiders sold within 30 days and 80 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (1 buy, 9 sales), the last on Feb 17, 2026.
- The trade is 3.5% of the 268,851 shares held after it.
- 2 other insiders sold within 30 days.
- 80 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive VP, Finance and CFO GUSTAFSON KURT A sold about $15.9K of OABI on Feb 18, 2026; 2 other insiders sold within 30 days and 80 funds added in the latest 13F quarter.56 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
80 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
7.2% of the float short (float per yahoo 2026-10-27) · 6.7 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch OABI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+188.1%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns OABI: institutional holders (13F)
13F holdings, latest reported quarter
10,248,658 sh
$25.2M
8,897,490 sh
$21.9M
5,028,160 sh
$12.4M
4,211,821 sh
$10.4M
3,852,356 sh
$9.5M
Congress trades in OABI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
OABI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
OABI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$455.1K position · as of 2026-06-30
0.3%
Clearwater Select Equity Fund
$581.8K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$907.9K position · as of 2026-06-30
0.1%
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF
$326.5K position · as of 2026-05-31
0.0%
Invesco Nasdaq Biotechnology ETF
$20.5K position · as of 2026-05-31
0.0%
1290 VT Micro Cap Portfolio
$61.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 80 funds added last quarter. Each figure is a federal filing, dated the day it went public.
OABI Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
